- Home
- MSTR vs EW Comparison
MSTR vs EW Comparison
Compare MSTR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSTR | EW |
|---|---|---|
| Founded | 1989 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4B | 50.2B |
| IPO Year | 1998 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MSTR | EW |
|---|---|---|
| Price | $135.89 | $81.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $349.15 | $96.47 |
| AVG Volume (30 Days) | ★ 15.6M | 4.1M |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | $463,456,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | $4.59 | $13.39 |
| Revenue Next Year | $0.38 | $9.78 |
| P/E Ratio | ★ N/A | $45.10 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $105.00 | $65.94 |
| 52 Week High | $457.22 | $87.89 |
Technical Indicators
Market Signals| Indicator | MSTR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 45.95 |
| Support Level | $118.40 | $80.91 |
| Resistance Level | $150.91 | $82.64 |
| Average True Range (ATR) | 6.18 | 2.14 |
| MACD | 0.17 | -0.34 |
| Stochastic Oscillator | 20.10 | 21.77 |
Price Performance
Historical ComparisonAbout MSTR MicroStrategy Incorporated
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.